MarketPeel
Insider Trading Intelligence
Pricing
…
DH

David T. Howton

SRPT
EVP, GENERAL COUNSEL · SAREPTA THERAPEUTICS, INC. · CIK 0001529297
FILING MIX · LIFETIME51%/49%
BUYS
23
SELLS
22
TOTAL VALUE
$21.17M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
242,070
AVG SELL PX
$97.07
TRADE KIND
SHOWING 45 / 45
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
11 backtested trades · 8 horizons · 13 pending
Forward-return performance of every backtestable P/S trade by David T. Howton, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d11+54.55%+5.89%-0.58%+6.47%-2.33%—
14d11+63.64%+3.00%+0.53%+2.48%-6.85%—
30d11+54.55%+7.43%+0.46%+6.98%-3.03%—
60d11+54.55%+5.97%+2.69%+3.28%-21.44%—
90d11+54.55%+10.82%+4.17%+6.65%+0.20%—
180d11(3 pending)+12.50%+28.03%+14.36%+11.76%-17.68%—
1y11(4 pending)+57.14%-15.74%+30.45%-46.19%-91.88%—
2y11(6 pending)+80.00%-38.00%+29.80%-67.80%-84.28%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SRPT · 136,993 shares · as of Jun 22, 2020
034,24868,497102,745136,993SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 23 buys / 22 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SLDB
SOLID BIOSCIENCES INC.
SALE10b5-1
10b5-1 plan
7,469$5.82$43.5K105,077Feb 18, 2026Feb 18, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
14,687——29,376Feb 13, 2026Feb 18, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASE
Chief Operating Officer
14,687——112,546Feb 13, 2026Feb 18, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE10b5-1
10b5-1 plan
18,894$6.44$121.7K97,859Feb 4, 2026Feb 6, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE10b5-1
10b5-1 plan
37,771$6.44$243.1K116,753Feb 2, 2026Feb 2, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASE
Chief Operating Officer
42,275——154,254Jan 31, 2026Feb 2, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
42,275——126,825Jan 31, 2026Feb 2, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
79,341——0Jan 29, 2026Feb 2, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASE
Chief Operating Officer
79,341——112,249Jan 29, 2026Feb 2, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
210,200——210,200Jan 29, 2026Feb 2, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
105,100——105,100Jan 29, 2026Feb 2, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
79,341——79,341Jan 29, 2026Apr 21, 2026 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE10b5-1
10b5-1 plan
4,932$5.11$25.2K32,908Dec 3, 2025Dec 4, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
13,051——13,052Dec 2, 2025Dec 4, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASE
Chief Operating Officer
13,051——37,840Dec 2, 2025Dec 4, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
75,000——75,000Aug 14, 2025Aug 18, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
150,000——150,000Aug 14, 2025Aug 18, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE10b5-1
10b5-1 plan
5,561$3.96$22.0K24,789Feb 14, 2025Feb 18, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
14,687——44,063Feb 13, 2025Feb 18, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASE
Chief Operating Officer
14,687——30,350Feb 13, 2025Feb 18, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
169,100——169,100Jan 31, 2025Feb 11, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
5,072$5.60$28.4K15,663Dec 3, 2024Dec 4, 2024 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASE
Chief Operating Officer
13,051——20,735Dec 2, 2024Dec 4, 2024 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
13,051——26,103Dec 2, 2024Dec 4, 2024 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
58,750——58,750Feb 13, 2024Feb 16, 2024 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
117,500——117,500Feb 13, 2024Feb 16, 2024 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
5,367$2.78$14.9K7,684Dec 4, 2023Dec 5, 2023 ↗View →
SLDB
SOLID BIOSCIENCES INC.
SALE
Chief Operating Officer
13,051——39,154Dec 2, 2023Dec 5, 2023 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASE
Chief Operating Officer
13,051——13,051Dec 2, 2023Dec 5, 2023 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
104,410——104,410Dec 2, 2022Dec 5, 2022 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
52,205——52,205Dec 2, 2022Dec 5, 2022 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASE
EVP, General Counsel
1,858$13.71$25.5K35,009Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, General Counsel
45,000——7,708Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, General Counsel
8,086$169.56$1.37M122,898Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, General Counsel
1,280——0Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASE
EVP, General Counsel
56,984$23.85$1.36M91,993Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASE
EVP, General Counsel
1,280$13.71$17.5K33,151Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, General Counsel
56,984——0Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, General Counsel
35,757$170.59$6.10M87,141Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, General Counsel
55,270$171.50$9.48M31,871Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, General Counsel
6,009$168.61$1.01M130,984Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
EVP, General Counsel
1,858——0Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASE
EVP, General Counsel
45,000$29.03$1.31M136,993Jun 22, 2020Jun 22, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,500——37,500Feb 28, 2020Feb 28, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,700——31,871Feb 28, 2020Feb 28, 2020 ↗View →
Other insiders · SRPT
Loading peer insiders…
About this filer
CIK 0001529297
ROLE
EVP, General Counsel
PRIMARY
SRPT
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001529297DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback